Indian pharma sector — generics + US exports
Indian pharma sector — Sun Pharma, Dr Reddy's, Cipla, Lupin, Divi's Labs. Live prices, USFDA observations, US generic pricing cycle, India-domestic formulation growth. Refreshed daily.
Why this sector matters
Indian pharma has two very different businesses stapled together: (1) the India domestic branded formulation market — 10–12% annual growth, high ROCE, stable; and (2) US generic exports — commoditised, subject to USFDA quality-audit risk + pricing erosion. Specialty / complex-generic players (Sun, Dr Reddy's, Aurobindo) are working to escape the generic erosion; CDMO (Divi's) is a separate capex-heavy B2B play. USFDA warning letters are the single biggest stock-price catalyst.
Key drivers to track
- • USFDA facility inspection outcomes — Form 483 observations vs warning letters
- • US generic pricing erosion — typically 5–10% per year in commodity generics
- • India formulation growth (IPM data) — 10–12% CAGR baseline
- • Complex-generics + specialty launches — escapes commodity-generic margin compression
- • Regulatory approvals (ANDA) — a leading indicator of revenue 2–3 quarters out
Explore more sectors
Ask Axel for a pharma sector deep-dive
Axel can layer qualitative analysis on top of the live pharma data — management quality flags, regulatory headwinds, recent results tone across the top constituents. Research framing, not a recommendation.
Research tool · not investment advice.
Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Sector data sourced from NSE public feeds + our own XBRL parsing of company filings. Constituents shown are NIFTY 50 + Next 50 + curated midcap members tagged to the pharma sector; may not be an exhaustive universe. Not investment advice — sector classifications and screener results are informational only.